

[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)[Cases](#)

Your wildcard search against 2000 terms has yielded the results below

Search for additional matches among the next 2000 terms
starting with: PRO\$(PROAPORPHINIC).AB.

Search Results -

Terms	Documents
l2 and (pro\$).ab.	25

US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index

Database: IBM Technical Disclosure Bulletins

Search:

L7

[Refine Search](#)

[Recall Text](#)

[Clear](#)

Search History

DATE: Wednesday, June 12, 2002 [Printable Copy](#) [Create Case](#)

Set Name Query


side by side

Hit Count Set Name

result set

DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=OR

<u>L7</u>	l2 and (pro\$).ab.	25	<u>L7</u>
<u>L6</u>	l1 and (\$mg.2).ab.	0	<u>L6</u>
<u>L5</u>	pro-c-mg\$	0	<u>L5</u>
<u>L4</u>	"pro-c-mg.2"	0	<u>L4</u>
<u>L3</u>	L2 and (polypep\$ OR protein).ab.	37	<u>L3</u>
<u>L2</u>	L1 and (angiogen\$).ab.	39	<u>L2</u>
<u>L1</u>	(gerritsen-m\$ or goddard-a\$ or grimaldi-j\$ or mehraban-f\$).in.	212	<u>L1</u>



END OF SEARCH HISTORY



Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SPNETALE44/GXN

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Jan 23 BLAST(R) searching in REGISTRY available in STN on the Web
NEWS 3 Jan 23 FSTA has been reloaded and moves to weekly updates
NEWS 4 Feb 01 DKILIT now produced by RIZ Karlsruhe and has a new update frequency
NEWS 5 Feb 19 Access via Tymnet and SprintNet Eliminated Effective 3/31/02
NEWS 6 Mar 04 Gene Names now available in BIOSIS
NEWS 7 Mar 21 TOXLIT no longer available
NEWS 8 Mar 21 TROTHERMO no longer available
NEWS 9 Mar 21 US Provisional Priorities searched with P in CA/CAPLUS and USPATFULL
NEWS 10 Mar 21 LIPINSKI.CALC added for property searching in REGISTRY
NEWS 11 Apr 01 PAPERCHEM no longer available on STN. Use PAPERCHEM2 instead.
NEWS 12 Apr 01 "Ask CAS" for self-help around the clock
NEWS 13 Apr 03 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 14 Apr 03 ZDB will be removed from STN
NEWS 15 Apr 13 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 16 Apr 21 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 17 Apr 21 BIOSIS Gene Names now available in TOXCENTER
NEWS 18 Apr 21 Federal Research in Progress (FEDRIP) now available
NEWS 19 Jun 03 New e-mail delivery for search results now available
NEWS 20 Jun 10 MEDLINE Reload
NEWS 21 Jun 10 PCTFULL has been reloaded

NEWS EXPRESS February 1 CURRENT WINDOWS VERSION IS V6.0d,
CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
AND CURRENT DISCOVER FILE IS DATED 01 FEBRUARY 2002
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer Agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.



.....
FILE 'HOME' ENTERED AT 18:19:21 ON 12 JUN 2002

> file bioscience

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS

FILE ESTIMATED COST

SINCE FILE
ENTRY
0.21

TOTAL
SESSION
0.21

FILE 'ADISALERTS' ENTERED AT 18:19:45 ON 12 JUN 2002
COPYRIGHT (C) 2002 Adis International Ltd. (ADIS)

FILE 'ADISINSIGHT' ENTERED AT 18:19:45 ON 12 JUN 2002
COPYRIGHT (C) 2002 Adis International Ltd. (ADIS)

FILE 'ADISNEWS' ENTERED AT 18:19:45 ON 12 JUN 2002
COPYRIGHT (C) 2002 Adis International Ltd. (ADIS)

FILE 'AGRICOLA' ENTERED AT 18:19:45 ON 12 JUN 2002

FILE 'ANABSTR' ENTERED AT 18:19:45 ON 12 JUN 2002
COPYRIGHT (C) 2002 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'AQUASCI' ENTERED AT 18:19:45 ON 12 JUN 2002
(c) 2002 FAO (on behalf of the ASFA Advisory Board) All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 18:19:45 ON 12 JUN 2002
COPYRIGHT (C) 2002 Biological Abstracts, Inc. (BIOSIS)

FILE 'BIOCOMMERCE' ENTERED AT 18:19:45 ON 12 JUN 2002
COPYRIGHT (C) 2002 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All rights reserved

FILE 'BIOSIS' ENTERED AT 18:19:45 ON 12 JUN 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 18:19:45 ON 12 JUN 2002
COPYRIGHT (C) 2002 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'BIOTECHNO' ENTERED AT 18:19:45 ON 12 JUN 2002
COPYRIGHT (C) 2002 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 18:19:45 ON 12 JUN 2002
COPYRIGHT (C) 2002 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 18:19:45 ON 12 JUN 2002

FILE 'CARBUS' ENTERED AT 18:19:45 ON 12 JUN 2002
THE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEARA-UTR' ENTERED AT 18:19:45 ON 12 JUN 2002
COPYRIGHT (c) 2002 DECHEMA eV



FILE 'CEN' ENTERED AT 18:19:45 ON 12 JUN 2002
COPYRIGHT (C) 2002 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 18:19:45 ON 12 JUN 2002
SITE IS SUBJECT TO THE TERMS OF YOUR SITE CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 18:19:45 ON 12 JUN 2002
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'CROPB' ENTERED AT 18:19:45 ON 12 JUN 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'CROPU' ENTERED AT 18:19:45 ON 12 JUN 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'COPB' ACCESS NOT AUTHORIZED

FILE 'COPU' ACCESS NOT AUTHORIZED

FILE 'CGENE' ENTERED AT 18:19:45 ON 12 JUN 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'CUGB' ENTERED AT 18:19:45 ON 12 JUN 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'CUGLAUNCH' ENTERED AT 18:19:45 ON 12 JUN 2002
COPYRIGHT (C) 2002 IMSWORLD Publications Ltd

FILE 'CUGMONOG2' ENTERED AT 18:19:45 ON 12 JUN 2002
COPYRIGHT (C) 2002 IMSWORLD Publications Ltd

FILE 'CUGNL' ENTERED AT 18:19:45 ON 12 JUN 2002
COPYRIGHT (C) 2002 IMSWORLD Publications Ltd

FILE 'CUGU' ENTERED AT 18:19:45 ON 12 JUN 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

FILE 'CUGUPDATES' ENTERED AT 18:19:45 ON 12 JUN 2002
COPYRIGHT (C) 2002 IMSWORLD Publications Ltd

FILE 'EMBAL' ENTERED AT 18:19:45 ON 12 JUN 2002
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'EMBASE' ENTERED AT 18:19:45 ON 12 JUN 2002
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 18:19:45 ON 12 JUN 2002
COPYRIGHT (C) 2002 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEEDRID' ENTERED AT 18:19:45 ON 12 JUN 2002

FILE 'FOMAD' ENTERED AT 18:19:45 ON 12 JUN 2002
COPYRIGHT (C) 2002 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 18:19:45 ON 12 JUN 2002
COPYRIGHT (C) 2002 Leatherhead Food Research Association



FILE 'FROST' ENTERED AT 18:19:45 ON 12 JUN 2002
COPYRIGHT (C) 2002 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 18:19:45 ON 12 JUN 2002
COPYRIGHT (C) 2002 International Food Information Service

FILE 'GENBANK' ENTERED AT 18:19:45 ON 12 JUN 2002

FILE 'HEALSAPP' ENTERED AT 18:19:45 ON 12 JUN 2002
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 18:19:45 ON 12 JUN 2002
COPYRIGHT (C) 2002 IFI CLAIMS(R) Patent Services (IFI)

FILE 'JICST-EPLUS' ENTERED AT 18:19:45 ON 12 JUN 2002
COPYRIGHT (C) 2002 Japan Science and Technology Corporation (JST)

FILE 'COSMEI' ENTERED AT 18:19:45 ON 12 JUN 2002
COPYRIGHT (C) 2002 International Federation of the Societies of Cosmetics
Dermatists

FILE 'LIFESCI' ENTERED AT 18:19:45 ON 12 JUN 2002
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONE' ENTERED AT 18:19:45 ON 12 JUN 2002
COPYRIGHT (C) 2002 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 18:19:45 ON 12 JUN 2002

FILE 'NIOSHPIC' ENTERED AT 18:19:45 ON 12 JUN 2002
COPYRIGHT (C) 2002 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 18:19:45 ON 12 JUN 2002
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2002)

FILE 'OCEAN' ENTERED AT 18:19:45 ON 12 JUN 2002
COPYRIGHT (C) 2002 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 18:19:45 ON 12 JUN 2002
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2002 INIST-CNRS. All rights reserved.

FILE 'PHAR' ENTERED AT 18:19:45 ON 12 JUN 2002
COPYRIGHT (C) 2002 PJB Publications Ltd. (PJB)

FILE 'THIC' ENTERED AT 18:19:45 ON 12 JUN 2002
COPYRIGHT (C) 2002 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 18:19:45 ON 12 JUN 2002
COPYRIGHT (C) 2002 PJB Publications Ltd. (PJB)

FILE 'PROMT' ENTERED AT 18:19:45 ON 12 JUN 2002
COPYRIGHT (C) 2002 Gale Group. All rights reserved.



FILE 'JSCSEARCH' ENTERED AT 18:19:45 ON 12 JUN 2002
COPYRIGHT (C) 2002 Institute for Scientific Information (ISI, ISI)

FILE 'SYNTHLINE' ENTERED AT 18:19:45 ON 12 JUN 2002
COPYRIGHT (C) 2002 Freds Science

FILE 'TOXCENTER' ENTERED AT 18:19:45 ON 12 JUN 2002
COPYRIGHT (C) 2002 ACS

FILE 'USPATFULL' ENTERED AT 18:19:45 ON 12 JUN 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 18:19:45 ON 12 JUN 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 18:19:45 ON 12 JUN 2002
COPYRIGHT (C) 2002 THOMSON DEFWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

-- s "PRO-C-MG.2"
15 FILES SEARCHED...
36 FILES SEARCHED...
54 FILES SEARCHED...
L1 11 "PRO-C-MG.2"

-- dup rem l1
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, CGENE,
DRUGLAUNCH, DRUGMONOG2, DRUGUPDATES, FEDRIP, FOREGE, GENBANK, KOSMET,
MEDICONE, PHAR, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L1
L1 10 DUP REM L1 (1 DUPLICATE REMOVED)

-- d 1-1

L1 ANSWER 1 OF 10 PROMT COPYRIGHT 2002 Gale Group

ACCESSION NUMBER: 2001:372498 PROMT
TITLE: COMPANY.
SOURCE: Implement & Tractor, (Annual 2001) pp. 4.
ISSN: 0019-2953.
PUBLISHER: Freiburg Publishing Co. Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 73063
FULL TEXT IS AVAILABLE IN THE AIL FORMAT

L2 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 1
AN 2001:2605e4 CAPLUS
DN 104:291146
TI human polypeptides and their encoding nucleic acids for use in
angiogenesis and vascularization
IN Gerritsen, Mary E.; Goddard, Audrey; Grimaldi, J. Christopher; Menraban,
Flad
PA Genentech, Inc., USA; Curagen Corporation
SO PCT Int. Appl., 189 pp.
CODEN: PIXXD2
DT Patent



LA English

PAN. CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001025433	A2	20010412	WO 2000-0327512	20001006
	WO 2001025433	A3	20011122		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BE, BG, BF, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GR, HU, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AE, AY, KB, KA, MD, RE, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRA1 US 1999-153587P P 19991007
US 1999-162611P P 19991028

L2 ANSWER 3 OF 10 PROMT COPYRIGHT 2002 Gale Group

ACCESSION NUMBER: 2001:152547 PROMT
TITLE: Manufacturers.
SOURCE: Canadian Machinery and Metalworking, (Dec 2000) Vol. 95, No. 10, pp. 103.
ISSN: 0008-4378.
PUBLISHER: Maclean Hunter Canadian Publishing Ltd.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 64708
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L2 ANSWER 4 OF 10 PROMT COPYRIGHT 2002 Gale Group

ACCESSION NUMBER: 2000:453252 PROMT
TITLE: COMPANY. (Buyers Guide)
SOURCE: Implement & Tractor, (Annual 2000) pp. 4.
ISSN: 0019-2953.
PUBLISHER: Freiburg Publishing Co. Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 81211
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L2 ANSWER 5 OF 10 DGENE (C) 2002 THOMSON DERWENT
AN AAE02775 Protein DGENE
TI Polypeptides critical for angiogenesis and vascularization, and the nucleic acids encoding them, useful for treating conditions related to inappropriate vascularization and angiogenesis -
IN Gerritsen M E; Goddard A; Grimaldi J C; Mehraban F
PA (GETH) GENENTECH INC.
(CURA-N) CURAGEN CORP.
PI WO 2001025433 A2 20010412 179p
AI WO 2000-0327512 20001006
PRA1 US 1999-158587 19991007
US 1999-162611 19991028
DI Patent
LA English
CS 2001-167229 [38]

L2 ANSWER 6 OF 10 DGENE (C) 2002 THOMSON DERWENT



L2 ANSWER 7 OF 10 DGENE (C) 2002 THOMSON DERWENT
 AN AAD07047 DNA DGENE
 TI Polypeptides critical for angiogenesis and vascularization, and the nucleic acids encoding them, useful for treating conditions related to inappropriate vascularization and angiogenesis -
 IN Gerritsen M E; Goddard A; Grimaldi J C; Mehraban F
 EA (GETH) GENENTECH INC.
 (CURA-N) CURAGEN CORP.
 FI WO 2001025433 A2 20010412 189p
 AI WO 2000-US-7512 20001015
 FRAI US 1999-15-537 19991017
 US 1999-16-611 19991018
 DI Patent
 LA English
 CS 2001-36722, [38]

L2 ANSWER 7 OF 10 DGENE (C) 2002 THOMSON DERWENT
 AN AAD07047 DNA DGENE
 TI Polypeptides critical for angiogenesis and vascularization, and the nucleic acids encoding them, useful for treating conditions related to inappropriate vascularization and angiogenesis -
 IN Gerritsen M E; Goddard A; Grimaldi J C; Mehraban F
 EA (GETH) GENENTECH INC.
 (CURA-N) CURAGEN CORP.
 FI WO 2001025433 A2 20010412 189p
 AI WO 2000-US-7512 20001015
 FRAI US 1999-15-537 19991017
 US 1999-16-611 19991018
 IT Patent
 LA English
 CS 2001-36722, [38]

L2 ANSWER 8 OF 10 DGENE (C) 2002 THOMSON DERWENT
 AN AAD07046 DNA DGENE
 TI Polypeptides critical for angiogenesis and vascularization, and the nucleic acids encoding them, useful for treating conditions related to inappropriate vascularization and angiogenesis -
 IN Gerritsen M E; Goddard A; Grimaldi J C; Mehraban F
 EA (GETH) GENENTECH INC.
 (CURA-N) CURAGEN CORP.
 FI WO 2001025433 A2 20010412 189p
 AI WO 2000-US-7512 20001015
 FRAI US 1999-15-537 19991017
 US 1999-16-611 19991018
 IT Patent
 LA English
 CS 2001-36722, [38]

L2 ANSWER 9 OF 10 DGENE (C) 2002 THOMSON DERWENT
 AN AAD07045 DNA DGENE
 TI Polypeptides critical for angiogenesis and vascularization, and the nucleic acids encoding them, useful for treating conditions related to inappropriate vascularization and angiogenesis -
 IN Gerritsen M E; Goddard A; Grimaldi J C; Mehraban F
 EA (GETH) GENENTECH INC.
 (CURA-N) CURAGEN CORP.
 FI WO 2001025433 A2 20010412 189p
 AI WO 2000-US-7512 20001015
 FRAI US 1999-15-537 19991017
 US 1999-16-611 19991018
 DT Patent



LA English
OS 2001-367229 [38]

L2 ANSWER 15 OF 19 DGENE (U) 2002 THOMSON DEWEENT
AN AAD07043 cDNA DGENE
TI Polypeptides critical for angiogenesis and vascularization, and the
nucleic acids encoding them, useful for treating conditions related to
inappropriate vascularization and angiogenesis -
IN Gerritsen M F; Goddard A; Grimaldi J C; Menraban F
PA (GETH) GENENTECH INC.
(CURA-N) CURAGEN CORP.
PI WO 2001025433 A2 20010412 1esp
AI WO 2000-0527512 20001005
PRAI US 1999-158587 19991007
US 1999-162611 19991028
DT Patent
LA English
OS 2001-367229 [38]



STANDARD SERVICE OF
 THE
 NATIONAL ASSOCIATION OF
 REALTORS
 1934

[illegible]

1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025, 2026, 2027, 2028, 2029, 2030, 2031, 2032, 2033, 2034, 2035, 2036, 2037, 2038, 2039, 2040, 2041, 2042, 2043, 2044, 2045, 2046, 2047, 2048, 2049, 2050, 2051, 2052, 2053, 2054, 2055, 2056, 2057, 2058, 2059, 2060, 2061, 2062, 2063, 2064, 2065, 2066, 2067, 2068, 2069, 2070, 2071, 2072, 2073, 2074, 2075, 2076, 2077, 2078, 2079, 2080, 2081, 2082, 2083, 2084, 2085, 2086, 2087, 2088, 2089, 2090, 2091, 2092, 2093, 2094, 2095, 2096, 2097, 2098, 2099, 2100, 2101, 2102, 2103, 2104, 2105, 2106, 2107, 2108, 2109, 2110, 2111, 2112, 2113, 2114, 2115, 2116, 2117, 2118, 2119, 2120, 2121, 2122, 2123, 2124, 2125, 2126, 2127, 2128, 2129, 2130, 2131, 2132, 2133, 2134, 2135, 2136, 2137, 2138, 2139, 2140, 2141, 2142, 2143, 2144, 2145, 2146, 2147, 2148, 2149, 2150, 2151, 2152, 2153, 2154, 2155, 2156, 2157, 2158, 2159, 2160, 2161, 2162, 2163, 2164, 2165, 2166, 2167, 2168, 2169, 2170, 2171, 2172, 2173, 2174, 2175, 2176, 2177, 2178, 2179, 2180, 2181, 2182, 2183, 2184, 2185, 2186, 2187, 2188, 2189, 2190, 2191, 2192, 2193, 2194, 2195, 2196, 2197, 2198, 2199, 2200, 2201, 2202, 2203, 2204, 2205, 2206, 2207, 2208, 2209, 2210, 2211, 2212, 2213, 2214, 2215, 2216, 2217, 2218, 2219, 2220, 2221, 2222, 2223, 2224, 2225, 2226, 2227, 2228, 2229, 2230, 2231, 2232, 2233, 2234, 2235, 2236, 2237, 2238, 2239, 2240, 2241, 2242, 2243, 2244, 2245, 2246, 2247, 2248, 2249, 2250, 2251, 2252, 2253, 2254, 2255, 2256, 2257, 2258, 2259, 2260, 2261, 2262, 2263, 2264, 2265, 2266, 2267, 2268, 2269, 2270, 2271, 2272, 2273, 2274, 2275, 2276, 2277, 2278, 2279, 2280, 2281, 2282, 2283, 2284, 2285, 2286, 2287, 2288, 2289, 2290, 2291, 2292, 2293, 2294, 2295, 2296, 2297, 2298, 2299, 2300, 2301, 2302, 2303, 2304, 2305, 2306, 2307, 2308, 2309, 2310, 2311, 2312, 2313, 2314, 2315, 2316, 2317, 2318, 2319, 2320, 2321, 2322, 2323, 2324, 2325, 2326, 2327, 2328, 2329, 2330, 2331, 2332, 2333, 2334, 2335, 2336, 2337, 2338, 2339, 2340, 2341, 2342, 2343, 2344, 2345, 2346, 2347, 2348, 2349, 2350, 2351, 2352, 2353, 2354, 2355, 2356, 2357, 2358, 2359, 2360, 2361, 2362, 2363, 2364, 2365, 2366, 2367, 2368, 2369, 2370, 2371, 2372, 2373, 2374, 2375, 2376, 2377, 2378, 2379, 2380, 2381, 2382, 2383, 2384, 2385, 2386, 2387, 2388, 2389, 2390, 2391, 2392, 2393, 2394, 2395, 2396, 2397, 2398, 2399, 2400, 2401, 2402, 2403, 2404, 2405, 2406, 2407, 2408, 2409, 2410, 2411, 2412, 2413, 2414, 2415, 2416, 2417, 2418, 2419, 2420, 2421, 2422, 2423, 2424, 2425, 2426, 2427, 2428, 2429, 2430, 2431, 2432, 2433, 2434, 2435, 2436, 2437, 2438, 2439, 2440, 2441, 2442, 2443, 2444, 2445, 2446, 2447, 2448, 2449, 2450, 2451, 2452, 2453, 2454, 2455, 2456, 2457, 2458, 2459, 2460, 2461, 2462, 2463, 2464, 2465, 2466, 2467, 2468, 2469, 2470, 2471, 2472, 2473, 2474, 2475, 2476, 2477, 2478, 2479, 2480, 2481, 2482, 2483, 2484, 2485, 2486, 2487, 2488, 2489, 2490, 2491, 2492, 2493, 2494, 2495, 2496, 2497, 2498, 2499, 2500, 2501, 2502, 2503, 2504, 2505, 2506, 2507, 2508, 2509, 2510, 2511, 2512, 2513, 2514, 2515, 2516, 2517, 2518, 2519, 2520, 2521, 2522, 2523, 2524, 2525, 2526, 2527, 2528, 2529, 2530, 2531, 2532, 2533, 2534, 2535, 2536, 2537, 2538, 2539, 2540, 2541, 2542, 2543, 2544, 2545, 2546, 2547, 2548, 2549, 2550, 2551, 2552, 2553, 2554, 2555, 2556, 2557, 2558, 2559, 2560, 2561, 2562, 2563, 2564, 2565, 2566, 2567, 2568, 2569, 2570, 2571, 2572, 2573, 2574, 2575, 2576, 2577, 2578, 2579, 2580, 2581, 2582, 2583, 2584, 2585, 2586, 2587, 2588, 2589, 2590, 2591, 2592, 2593, 2594, 2595, 2596, 2597, 2598, 2599, 2600, 2601, 2602, 2603, 2604, 2605, 2606, 2607, 2608, 2609, 2610, 2611, 2612, 2613, 2614, 2615, 2616, 2617, 2618, 2619, 2620, 2621, 2622, 2623, 2624, 2625, 2626, 2627, 2628, 2629, 2630, 2631, 2632, 2633, 2634, 2635, 2636, 2637, 2638, 2639, 2640, 2641, 2642, 2643, 2644, 2645, 2646, 2647, 2648, 2649, 2650, 2651, 2652, 2653, 2654, 2655, 2656, 2657, 2658, 2659, 2660, 2661, 2662, 2663, 2664, 2665, 2666, 2667, 2668, 2669, 2670, 2671, 2672, 2673, 2674, 2675, 2676, 2677, 2678, 26

Journal of Interpersonal Violence 25(4) 637-657
© The Author(s) 2010
Reprints and permissions: sagepub.com/journalsPermissions.nav
DOI: 10.1177/0886260510376821
http://jiv.sagepub.com

THE UNIVERSITY OF CHICAGO

of the number of bases or symbols chosen per parameter.

[illegible]

and N. 1 is the value of points credited by chance to have a score of 100. The value of σ^2 is the variance of the residuals being predicted by analysis of the total score distribution.

SIMPAA-1113

Accession No.	Species	Month	Length (hr)	Sex	Description
1	100000	6/7	99.6	♂	100000
2	100000	6/8	100.1	♂	100000
3	100000	6/9	100.6	♂	100000
4	100000	6/10	100.6	♂	100000
5	100000	6/11	100.6	♂	100000
6	100000	6/12	100.6	♂	100000
7	100000	6/13	100.6	♂	100000
8	100000	6/14	100.6	♂	100000
9	100000	6/15	100.6	♂	100000
10	100000	6/16	100.6	♂	100000
11	100000	6/17	100.6	♂	100000
12	100000	6/18	100.6	♂	100000
13	100000	6/19	100.6	♂	100000
14	100000	6/20	100.6	♂	100000
15	100000	6/21	100.6	♂	100000
16	100000	6/22	100.6	♂	100000
17	100000	6/23	100.6	♂	100000
18	100000	6/24	100.6	♂	100000
19	100000	6/25	100.6	♂	100000
20	100000	6/26	100.6	♂	100000
21	100000	6/27	100.6	♂	100000
22	100000	6/28	100.6	♂	100000
23	100000	6/29	100.6	♂	100000
24	100000	6/30	100.6	♂	100000
25	100000	6/31	100.6	♂	100000
26	100000	6/32	100.6	♂	100000
27	100000	6/33	100.6	♂	100000
28	100000	6/34	100.6	♂	100000
29	100000	6/35	100.6	♂	100000
30	100000	6/36	100.6	♂	100000
31	100000	6/37	100.6	♂	100000
32	100000	6/38	100.6	♂	100000
33	100000	6/39	100.6	♂	100000
34	100000	6/40	100.6	♂	100000
35	100000	6/41	100.6	♂	100000
36	100000	6/42	100.6	♂	100000
37	100000	6/43	100.6	♂	100000
38	100000	6/44	100.6	♂	100000
39	100000	6/45	100.6	♂	100000
40	100000	6/46	100.6	♂	100000
41	100000	6/47	100.6	♂	100000
42	100000	6/48	100.6	♂	100000
43	100000	6/49	100.6	♂	100000
44	100000	6/50	100.6	♂	100000
45	100000	6/51	100.6	♂	100000
46	100000	6/52	100.6	♂	100000
47	100000	6/53	100.6	♂	100000
48	100000	6/54	100.6	♂	100000
49	100000	6/55	100.6	♂	100000
50	100000	6/56	100.6	♂	100000
51	100000	6/57	100.6	♂	100000
52	100000	6/58	100.6	♂	100000
53	100000	6/59	100.6	♂	100000
54	100000	6/60	100.6	♂	100000
55	100000	6/61	100.6	♂	100000
56	100000	6/62	100.6	♂	100000
57	100000	6/63	100.6	♂	100000
58	100000	6/64	100.6	♂	100000
59	100000	6/65	100.6	♂	100000
60	100000	6/66	100.6	♂	100000

[illegible]

11-11-11

RESULT	1
ST10_HUMAN	
ID	ST10_HUMAN STANDARD: PRT: 998 AA.
AC	094804; Q9U1W4;
DT	16-OCT-2001 (rel. 40, created)
DI	16-OCT-2001 (rel. 40, last sequence update)
DE	16-OCT-2001 (rel. 40, last annotation update)
DE	kinase/threonine-protein kinase-1 (EC 2.7.1.57) (lymphocyte protein kinase).
GN	SIK10 OR LOK.
OS	Homo sapiens (Human).
OC	Eukaryota; Metazoa; Chordata; Chordata Vertebrata; Euteleostomi;
OC	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX	NCBI_TaxID 9606;
RN	[1]
RF	SEQUENCE FROM N.A.
RE	MEHLING-9521644; PubMed 1019642.
RA	Karumachi S., Matsuda Y., Okumura M., Kikuchi T., Yokoyama H.,
RA	Karasuyama H.;
RT	"Molecular cloning of the human gene SIK1, encoding lymphocyte-
RT	oriented kinase, and comparative threonine and tyrosine phosphory-
RT	lenses, and rat homologues.";
RI	ImmunoGenetics 49:469-475(1999).
RN	[2]
RF	SEQUENCE OF 814-968 FROM N.A.
RC	LISINE testis;
RA	Bloncker H., Boecher M., Brand F., Meyers H., W. Glessnerhof J.,
RA	Wiemann S.;
KL	Submitted (Nov 1999) to the EMBL/GenBank/DDBJ databases.
CC	FUNCTION: CAN ACT ON SUBSTRATES SUCH AS RYR IN PART TO TURN OFF
CC	HEPATIC IAA RELEASE AND THEREBY REDUCE IAA (STIMULABILITY).
CC	CAATALYTIC ACTIVITY: ATP + a protein -> ADP + a phosphorylated
CC	protein; EC:2.7.1.57; EXACT AND PROBABLY IN WITH OTHER MEMBERS
CC	1. WITH AUTOPHOSPHORYLATION (ATP + PROTEIN -> ADP +
CC	1. STIMULATORY PROTEINS TO THE GINGIVIBIN FAMILY OF PROTEIN KINASES,
CC	SIEZO SUBFAMILY.
CC	
CC	THIS SWISS-PROT entry is copyright 1999. It is provided through a collaboration
CC	between the Swiss Institute of Bioinformatics and the EMBL database.
CC	the European Bioinformatics Institute. It is not to be redistributed or
CC	used by non-profit institutions as long as its content is not in the
CC	modified and this statement is not removed. Usage by and for commercial
CC	entities requires a license agreement. See: http://www.ebi.ac.uk/submit/
CC	or send an email to license@ebi.ac.uk.
DR	EMBL: AB015718; KAA50731.1
DR	EMBL: AC133081; ZAB61406.1
DR	HSSP: P24941; PROL.
DR	MIM: 604391;
DR	InterPro: IPRO00719; Euk_PKinase
DR	InterPro: IPRO02290; Ser_Thr_PKinase
DR	InterPro: IPRO1245; Tyr_PKinase
DR	PIR: P00069; PKinase7.1
DR	PRINIS: PR00104; TYRKINASE
DR	SMART: SM00220; S_TK_1
DR	PROSITE: PS00117; PROTEIN_KINASE_ATP_1

[illegible][illegible]

[illegible]

```

01 004 LIDEN ----- SLLGLSPYKSYFSFGRKINLESVVHVGCHL YEMVGRITDS 455
02      | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
03 016 DFGLSNLYOKRKITQITGDSPLVASTFIVNTRKATGGE VINSWATVILYLVV 1 250
04
05 054 VIVDSF----- PLVPS ----- MAVV----- AVLP----- 472
06      | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
07 051 MPPDQFDHRLIKLQSSGLYKRTLPDPAKRLIRSMALMVNPKRAFLHPLANHWVWQV 410
08
09 072 STGQVATGNT METGQGLLMLLETVVLLTTELEGGVETETGVALPAAVPTTER 429
10      | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
11 011 KSSVGLVALHVSSTPLAALDWEHRSFGLGADLE AKMK GLAPLTSIV 460
12
13 455 LLEGGVETETGVALPAAVPTTER 429 STGQVATGNT METGQGLLMLLETVVLLTTELEGGVETETGVALPAAVPTTER 429
14      | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
15 061 MLEKQPSKSGSGMPLAGLQAVVHVGCHLSTGQVETETGVALPAAVPTTER 414
16
17 059 GSGASSPLTSPSPPTTPT 511 SLLSALGPHVPPHPPAAVPTTASLTPVPAV 549
18      | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
19 015 GPE-----LEGVVGLALPSTFKMDLQTRGV-LLHSSP -----LEAVVGRKLS 455
20
21 059 SDAVNMSSGALLSLEQNPGR 561
22      | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
23 056 PEGSALMPEKTHFKTQKRS 477
24
25 RESULT 12
26 KPEE_RAT
27 ID KPEE_RAT STANDARD: PRT: 737 AA.
28 AC P09216;
29 01-MAR-1989 (Rel. 10, Cloned)
30 01-MAR-1989 (Rel. 10, Last sequence update)
31 15-JUL-1999 (Rel. 38, Last annotation update)
32 Protein kinase C, epsilon type (pI 2.7, 1.1) (NPKC-epsilon).
33 PKCE OR PKCE.
34 Ratios norvegicus (rat).
35 Fukuyota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
36 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
37 Mammalia; Eularchia; E-archonta; Sciuromorphi; Muridae; Murinae; Rattus.
38 NCBI_TaxID=10116;
39 11
40 RN
41 RT SEQUENCE FROM N.A.
42 KC TISSUE Brain;
43 RX MEDLINE 88198270; Pubmed 284497;
44 Gno Y., Fujii T., Ogita K., Kikawa H., Igarashi K., Nishizuka Y.,
45 "Identification of three additional members of rat protein kinase C
46 family: delta, epsilon, and zeta subtypes."
47 FEBS Lett. 226:125-128(1987).
48 1
49 1 FINGER, THIS IS CANONIC INTERPRET, THEREFORE INTERPRET.
50 CHROM AND THREE-DIMENSIONAL PREVIEW.
51 -1- FUNCTION: PKC IS ACTIVATED BY PHOSPHORYLATED WHICH IN TURN
52 PHOSPHORYLATES A RANGE OF CELLULAR PROTEINS. PKC ALSO SERVES AS
53 THE RECEPTOR FOR PHORBOL ESTERS, A CLASS OF TUMOR PROMOTERS.
54 1 SIMILARITY: CONTAINS 2 ZINC-DEPENDENT HYDROL ESTER AND DAD
55 BINDING DOMAINS.
56 1 SIMILARITY: CONTAINS 1 C2 DOMAIN.
57 1 IMMUNITY: 217 OF 737 RESIDUES ARE IN THE KINASES.
58 PKC SUBFAMILY.
59
60 This SWISS PRO entry is copyright. It is produced through a collaboration
61 between the Swiss Institute of Bioinformatics and the EMBL institution.
62 The European Bioinformatics Institute, there are no restrictions on its
63 use by non-profit institutions, and are the copyright is in no way
64 modified and this statement is not removed. Usage by and for commercial
65 entities requires a license agreement. See http://www.ebi.ac.uk/seqdb/doc/
66 or send an email to license@ebi.ac.uk.
67

```


Accession	Protein Name	Length	Mass	PI	Clade
1	1-1000	1000	1000	1000	1000
2	1-1000	1000	1000	1000	1000
3	1-1000	1000	1000	1000	1000
4	1-1000	1000	1000	1000	1000
5	1-1000	1000	1000	1000	1000
6	1-1000	1000	1000	1000	1000
7	1-1000	1000	1000	1000	1000
8	1-1000	1000	1000	1000	1000
9	1-1000	1000	1000	1000	1000
10	1-1000	1000	1000	1000	1000
11	1-1000	1000	1000	1000	1000
12	1-1000	1000	1000	1000	1000
13	1-1000	1000	1000	1000	1000
14	1-1000	1000	1000	1000	1000
15	1-1000	1000	1000	1000	1000
16	1-1000	1000	1000	1000	1000
17	1-1000	1000	1000	1000	1000
18	1-1000	1000	1000	1000	1000
19	1-1000	1000	1000	1000	1000
20	1-1000	1000	1000	1000	1000
21	1-1000	1000	1000	1000	1000
22	1-1000	1000	1000	1000	1000
23	1-1000	1000	1000	1000	1000
24	1-1000	1000	1000	1000	1000
25	1-1000	1000	1000	1000	1000
26	1-1000	1000	1000	1000	1000
27	1-1000	1000	1000	1000	1000
28	1-1000	1000	1000	1000	1000
29	1-1000	1000	1000	1000	1000
30	1-1000	1000	1000	1000	1000
31	1-1000	1000	1000	1000	1000
32	1-1000	1000	1000	1000	1000
33	1-1000	1000	1000	1000	1000
34	1-1000	1000	1000	1000	1000
35	1-1000	1000	1000	1000	1000
36	1-1000	1000	1000	1000	1000
37	1-1000	1000	1000	1000	1000
38	1-1000	1000	1000	1000	1000
39	1-1000	1000	1000	1000	1000
40	1-1000	1000	1000	1000	1000
41	1-1000	1000	1000	1000	1000
42	1-1000	1000	1000	1000	1000
43	1-1000	1000	1000	1000	1000
44	1-1000	1000	1000	1000	1000
45	1-1000	1000	1000	1000	1000
46	1-1000	1000	1000	1000	1000
47	1-1000	1000	1000	1000	1000
48	1-1000	1000	1000	1000	1000
49	1-1000	1000	1000	1000	1000
50	1-1000	1000	1000	1000	1000
51	1-1000	1000	1000	1000	1000
52	1-1000	1000	1000	1000	1000
53	1-1000	1000	1000	1000	1000
54	1-1000	1000	1000	1000	1000
55	1-1000	1000	1000	1000	1000
56	1-1000	1000	1000	1000	1000
57	1-1000	1000	1000	1000	1000
58	1-1000	1000	1000	1000	1000
59	1-1000	1000	1000	1000	1000
60	1-1000	1000	1000	1000	1000
61	1-1				

[illegible]

[illegible]

release : 2
date : 1994
http://www.fishbase.org/species/04621/ "Ocean habitat is clearings
and open water habitats"
collection : Oct-1999 #sequence revision 15-Oct-1999 #text_change 15-Oct-1999
Accession : 19994
identifier : A
submitted : The EMBL Data Library, December 1995
Accession number : Z19204

[illegible]

279	1 7 6	V I N G W A I D I O T E R Y	1 5 8	K I O K I O G O T I K I L E S T I H V Y K A R V A T A N E S S A I	4 2 5	1 1	2 2 5
280	1 7 7	V I N G W A I D I O T E R Y	1 5 9	K I O K I O G O T I K I L E S T I H V Y K A R V A T A N E S S A I	4 2 6	1 1	2 2 6
281	1 7 8	V A V A W T I L A S S E I N I E T E R G R E E A M E I L I G H T I V E	4 2 7	V I D W E S A I D I O G R E K R Y I V I V	4 2 8	1 1	4 2 8
282	1 7 9	M I N E K O T I K I E T Y A P P O C R E T E R Y	4 2 9	E N D E R G O T I L A S S E I K I Y O G I L E V K E L I O K O	4 2 9	1 1	2 8 3
283	1 8 0	E L I M S T I K	4 3 0	M Y L E K E S I N I E V	4 3 0	1 1	4 6 8
284	1 8 1	E T Y O H I	4 3 1	E H A N N A M A S S E I	4 3 1	1 1	3 2 4
285	1 8 2	E T Y O H I	4 3 2	E H A N N A M A S S E I	4 3 2	1 1	3 2 4
286	1 8 3	E T Y O H I	4 3 3	E H A N N A M A S S E I	4 3 3	1 1	3 2 4
287	1 8 4	E T Y O H I	4 3 4	E H A N N A M A S S E I	4 3 4	1 1	3 2 4
288	1 8 5	E T Y O H I	4 3 5	E H A N N A M A S S E I	4 3 5	1 1	3 2 4
289	1 8 6	E T Y O H I	4 3 6	E H A N N A M A S S E I	4 3 6	1 1	3 2 4
290	1 8 7	E T Y O H I	4 3 7	E H A N N A M A S S E I	4 3 7	1 1	3 2 4
291	1 8 8	E T Y O H I	4 3 8	E H A N N A M A S S E I	4 3 8	1 1	3 2 4
292	1 8 9	E T Y O H I	4 3 9	E H A N N A M A S S E I	4 3 9	1 1	3 2 4
293	1 9 0	E T Y O H I	4 4 0	E H A N N A M A S S E I	4 4 0	1 1	3 2 4
294	1 9 1	E T Y O H I	4 4 1	E H A N N A M A S S E I	4 4 1	1 1	3 2 4
295	1 9 2	E T Y O H I	4 4 2	E H A N N A M A S S E I	4 4 2	1 1	3 2 4
296	1 9 3	E T Y O H I	4 4 3	E H A N N A M A S S E I	4 4 3	1 1	3 2 4
297	1 9 4	E T Y O H I	4 4 4	E H A N N A M A S S E I	4 4 4	1 1	3 2 4
298	1 9 5	E T Y O H I	4 4 5	E H A N N A M A S S E I	4 4 5	1 1	3 2 4
299	1 9 6	E T Y O H I	4 4 6	E H A N N A M A S S E I	4 4 6	1 1	3 2 4
300	1 9 7	E T Y O H I	4 4 7	E H A N N A M A S S E I	4 4 7	1 1	3 2 4
301	1 9 8	E T Y O H I	4 4 8	E H A N N A M A S S E I	4 4 8	1 1	3 2 4
302	1 9 9	E T Y O H I	4 4 9	E H A N N A M A S S E I	4 4 9	1 1	3 2 4
303	2 0 0	E T Y O H I	4 5 0	E H A N N A M A S S E I	4 5 0	1 1	3 2 4
304	2 0 1	E T Y O H I	4 5 1	E H A N N A M A S S E I	4 5 1	1 1	3 2 4
305	2 0 2	E T Y O H I	4 5 2	E H A N N A M A S S E I	4 5 2	1 1	3 2 4
306	2 0 3	E T Y O H I	4 5 3	E H A N N A M A S S E I	4 5 3	1 1	3 2 4
307	2 0 4	E T Y O H I	4 5 4	E H A N N A M A S S E I	4 5 4	1 1	3 2 4
308	2 0 5	E T Y O H I	4 5 5	E H A N N A M A S S E I	4 5 5	1 1	3 2 4
309	2 0 6	E T Y O H I	4 5 6	E H A N N A M A S S E I	4 5 6	1 1	3 2 4
310	2 0 7	E T Y O H I	4 5 7	E H A N N A M A S S E I	4 5 7	1 1	3 2 4
311	2 0 8	E T Y O H I	4 5 8	E H A N N A M A S S E I	4 5 8	1 1	3 2 4
312	2 0 9	E T Y O H I	4 5 9	E H A N N A M A S S E I	4 5 9	1 1	3 2 4
313	2 1 0	E T Y O H I	4 6 0	E H A N N A M A S S E I	4 6 0	1 1	3 2 4
314	2 1 1	E T Y O H I	4 6 1	E H A N N A M A S S E I	4 6 1	1 1	3 2 4
315	2 1 2	E T Y O H I	4 6 2	E H A N N A M A S S E I	4 6 2	1 1	3 2 4
316	2 1 3	E T Y O H I	4 6 3	E H A N N A M A S S E I	4 6 3	1 1	3 2 4
317	2 1 4	E T Y O H I	4 6 4	E H A N N A M A S S E I	4 6 4	1 1	3 2 4
318	2 1 5	E T Y O H I	4 6 5	E H A N N A M A S S E I	4 6 5	1 1	3 2 4
319	2 1 6	E T Y O H I	4 6 6	E H A N N A M A S S E I	4 6 6		

[illegible][illegible]

Query Match	5.7%	Score 171.5	DB 27	Length 1228
Best Local Similarity	22.2%	Prod. No. 0.063		
Matches 113, Conservative	63, Mismatches	188	Indels 145	Gaps 22

[illegible]

14 KNTLSSST--NEKRIKAKIIPDSAP 174
15 KLAENSAEHSNSNISDIAEESIP 128

RESULT 4

16060

Subject: 141 Protein (D1044) - Monoclonal antibody of equine

cytochrome c monoclonal antibody

Created: 20-Sep-1999 #sequence_revision 20-Sep-1999 #text_change 20-Sep-1999

Accession: T10041

Reference: A

Submitted to the EMBL/GenBank/NCBI

Accession: T10041 #sequence_revision 20-Sep-1999 #text_change 20-Sep-1999

Accession: T10041

Accession: T10041

Accession: T10041

Accession: T10041

Accession: T10041

Accession: T10041

Accession: T10041

Accession: T10041

Accession: T10041

Accession: T10041

Accession: T10041

Accession: T10041

Accession: T10041

Accession: T10041

Accession: T10041

Accession: T10041

Accession: T10041

Accession: T10041

Accession: T10041

Accession: T10041

Accession: T10041

Accession: T10041

Accession: T10041

Accession: T10041

Accession: T10041

Accession: T10041

Accession: T10041

Accession: T10041

Accession: T10041

Accession: T10041

Accession: T10041

Accession: T10041

Accession: T10041

Accession: T10041

Accession: T10041

Accession: T10041

Accession: T10041

Accession: T10041

Accession: T10041

Accession: T10041

Accession: T10041

Accession: T10041

Accession: T10041

Accession: T10041

Accession: T10041

Accession: T10041

Accession: T10041

Accession: T10041

Accession: T10041

Accession: T10041

Accession: T10041

Accession: T10041

Accession: T10041

Accession: T10041

DB 759 INIAPKRNHSMAGETREPSIV LFNITKRSVGEISALDIIISRRVLESTRTAPR 818
CY 539 SSOA--VNGMSKCALISS 554
DB 819 SSSTEIKVSKJSDIIVSS 837

RESULT 5

16060

Subject: 5 Protein kinase C (EC 2.7.1.1) epsilon isoform

Cytochrome c (cytochrome c) (homocysteine)

Created: 20-Sep-1992 #sequence_revision 20-Sep-1992 #text_change 20-Sep-1992

Accession: A29880

Reference: A29880

Accession: A29880

Accession: A29880

Accession: A29880

Accession: A29880

Accession: A29880

Accession: A29880

Accession: A29880

Accession: A29880

Accession: A29880

Accession: A29880

Accession: A29880

Accession: A29880

Accession: A29880

Accession: A29880

Accession: A29880

Accession: A29880

Accession: A29880

Accession: A29880

Accession: A29880

Accession: A29880

Accession: A29880

Accession: A29880

Accession: A29880

Accession: A29880

Accession: A29880

Accession: A29880

Accession: A29880

Accession: A29880

Accession: A29880

Accession: A29880

Accession: A29880

Accession: A29880

Accession: A29880

Accession: A29880

Accession: A29880

Accession: A29880

Accession: A29880

Accession: A29880

Accession: A29880

Accession: A29880

Accession: A29880

Accession: A29880

Accession: A29880

Accession: A29880

Accession: A29880

Accession: A29880

Accession: A29880

Accession: A29880

Accession: A29880

Accession: A29880

Accession: A29880

Accession: A29880

Accession: A29880

Accession: A29880

Accession: A29880

[illegible][illegible]

[illegible]

PR	20-06T-2000; 200005-0241785.
PR	20-06T-2000; 200005-0241786.
PR	20-06T-2000; 200005-0241787.
PR	20-06T-2000; 200005-0241808.
PR	20-06T-2000; 200005-0241809.
PR	20-06T-2000; 200005-0241826.
PR	01-NOV-2000; 200005-0246617.
PR	08-NOV-2000; 200005-0246474.
PR	08-NOV-2000; 200005-0246475.
PR	08-NOV-2000; 200005-0246476.
PR	08-NOV-2000; 200005-0246477.
PR	08-NOV-2000; 200005-0246478.
PR	08-NOV-2000; 200005-0246523.
PR	08-NOV-2000; 200005-0246524.
PR	08-NOV-2000; 200005-0246525.
PR	08-NOV-2000; 200005-0246526.
PR	08-NOV-2000; 200005-0246527.
PR	08-NOV-2000; 200005-0246528.
PR	08-NOV-2000; 200005-0246532.
PR	08-NOV-2000; 200005-0246609.
PR	08-NOV-2000; 200005-0246610.
PR	08-NOV-2000; 200005-0246611.
PR	08-NOV-2000; 200005-0246613.
PR	17-NOV-2000; 200005-0249207.
PR	17-NOV-2000; 200005-0249208.
PR	17-NOV-2000; 200005-0249209.
PR	17-NOV-2000; 200005-0249210.
PR	17-NOV-2000; 200005-0249211.
PR	17-NOV-2000; 200005-0249212.
PR	17-NOV-2000; 200005-0249213.
PR	17-NOV-2000; 200005-0249214.
PR	17-NOV-2000; 200005-0249215.
PR	17-NOV-2000; 200005-0249216.
PR	17-NOV-2000; 200005-0249217.
PR	17-NOV-2000; 200005-0249218.
PR	17-NOV-2000; 200005-0249244.
PR	17-NOV-2000; 200005-0249245.
PR	17-NOV-2000; 200005-0249264.
PR	17-NOV-2000; 200005-0249265.
PR	17-NOV-2000; 200005-0249297.
PR	17-NOV-2000; 200005-0249299.
PR	17-NOV-2000; 200005-0249300.
PR	01-DEC-2000; 200005-0250160.
PR	01-DEC-2000; 200005-0250391.
PR	05-DEC-2000; 200005-0251030.
PR	05-DEC-2000; 200005-0251988.
PR	05-DEC-2000; 200005-0256719.
PR	05-DEC-2000; 200005-0251479.
PR	08-DEC-2000; 200005-0251856.
PR	08-DEC-2000; 200005-0251868.
PR	08-DEC-2000; 200005-0251869.
PR	08-DEC-2000; 200005-0251989.
PR	08-DEC-2000; 200005-0251990.
PR	11-DEC-2000; 200005-0254097.
PR	05-JAN-2001; 200105-0259678.
XX	
PA	(HUMA-) HUMAN GENOME SCI INC.
XX	
P1	Kosson CA, Barash SC, Ruben SM:
XX	
OR	WPI; 2001-465460/50.
OR	N-PSDH; AAS27387.
XX	
PT	Novel polypeptides useful for diagnosis, treatment, preventing and/or
PT	promoting disorders related to the proteins including cancers, immuno
PT	disorders and neuronal disorders
XX	
PS	Claim 1; SEQ ID No 1035; 880pp; English.
XX	
CC	The invention relates to novel isolated polypeptides (1), and
CC	polynucleotides (11), (1), (11) and the antibody to (1) are useful for
CC	diagnosis, preventing and treatment of diseases and of the immune system
CC	disorders (e.g. congenital and acquired immunodeficiencies, autoimmune

disorders (e.g. rheumatoid arthritis), inflammatory conditions, organ transplants, infectious and graft versus host disease, infectious diseases (e.g. hepatitis), blood disorders, haematobin abnormalities and other blood related disorders (stroke, cell anaemia), myeloproliferative disorders, primary haematopoietic disorders, hyperproliferative disorders (e.g. leukaemia's disease and cancer), neurodegenerative disorders (e.g. Alzheimer's disease, Parkinson's disease), chromosomal abnormalities (Down syndrome), haemorrhic injury (e.g. stroke, renal disorders (e.g. aneurysm, polycystitis), cardiovascular disorders (e.g. aneurysm), respiratory disorders, dermatological disorders, infectious diseases, reproductive system disorders, gastrointestinal disorders (intestine disorders), liver disorders (cirrhosis), neurological disorders of blood responsiveness to pathogens, activators of cell death, to interfere function affinity and bloodless and as means to induce death for laboratory use, pathological and accepted immune deficiency conditions (AIDS), AIDS type AIDS/684 represent novel stimuli transduction pathway pathway, immune and sequences of the invention.

[illegible]

1. The effect of the concentration of the solution on the rate of crystallization was studied. The results are shown in Figure 1. The rate of crystallization increases with increasing concentration of the solution. This is due to the fact that the rate of crystallization is proportional to the concentration of the solution.

41. **INTERNATIONAL JOURNAL OF THE HISTORY OF LINGUISTICS** 118

XX **16.** **17.**

XX **18.** **19.**

XX **20.** **21.**

XX **22.** **23.**

XX **24.** **25.**

XX **26.** **27.**

XX **28.** **29.**

XX **30.** **31.**

XX **32.** **33.**

XX **34.** **35.**

XX **36.** **37.**

XX **38.** **39.**

XX **40.** **41.**

XX **42.** **43.**

XX **44.** **45.**

XX **46.** **47.**

XX **48.** **49.**

XX **50.** **51.**

XX **52.** **53.**

XX **54.** **55.**

XX **56.** **57.**

XX **58.** **59.**

XX **60.** **61.**

XX **62.** **63.**

XX **64.** **65.**

XX **66.** **67.**

XX **68.** **69.**

XX **70.** **71.**

XX **72.** **73.**

XX **74.** **75.**

XX **76.** **77.**

XX **78.** **79.**

XX **80.** **81.**

XX **82.** **83.**

XX **84.** **85.**

XX **86.** **87.**

XX **88.** **89.**

XX **90.** **91.**

XX **92.** **93.**

XX **94.** **95.**

XX **96.** **97.**

XX **98.** **99.**

XX **100.** **101.**

XX **102.** **103.**

XX **104.** **105.**

XX **106.** **107.**

XX **108.** **109.**

XX **110.** **111.**

XX **112.** **113.**

XX **114.** **115.**

XX **116.** **117.**

XX **118.** **119.**

XX **120.** **121.**

XX **122.** **123.**

XX **124.** **125.**

XX **126.** **127.**

XX **128.** **129.**

XX **130.** **131.**

XX **132.** **133.**

XX **134.** **135.**

XX **136.** **137.**

XX **138.** **139.**

XX **140.** **141.**

XX **142.** **143.**

XX **144.** **145.**

XX **146.** **147.**

XX **148.** **149.**

XX **150.** **151.**

XX **152.** **153.**

XX **154.** **155.**

XX **156.** **157.**

XX **158.** **159.**

XX **160.** **161.**

XX **162.** **163.**

XX **164.** **165.**

XX **166.** **167.**

XX **168.** **169.**

XX **170.** **171.**

XX **172.** **173.**

XX **174.** **175.**

XX **176.** **177.**

XX **178.** **179.**

XX **180.** **181.**

XX **182.** **183.**

XX **184.** **185.**

XX **186.** **187.**

XX **188.** **189.**

XX **190.** **191.**

XX **192.** **193.**

XX **194.** **195.**

XX **196.** **197.**

XX **198.** **199.**

XX **200.** **201.**

XX **202.** **203.**

XX **204.** **205.**

XX **206.** **207.**

XX **208.** **209.**

XX **210.** **211.**

XX **212.** **213.**

XX **214.** **215.**

XX **216.** **217.**

XX **218.** **219.**

XX **220.** **221.**

XX **222.** **223.**

XX **224.** **225.**

XX **226.** **227.**

XX **228.** **229.**

XX **230.** **231.**

XX **232.** **233.**

XX **234.** **235.**

XX **236.** **237.**

XX **238.** **239.**

XX **240.** **241.**

XX **242.** **243.**

XX **244.** **245.**

XX **246.** **247.**

XX **248.** **249.**

XX **250.** **251.**

XX **252.** **253.**

XX **254.** **255.**

XX **256.** **257.**

XX **258.** **259.**

XX **260.** **261.**

XX **262.** **263.**

XX **264.** **265.**

XX **266.** **267.**

XX **268.** **269.**

XX **270.** **271.**

XX **272.** **273.**

XX **274.** **275.**

XX **276.**

Journal of Interpersonal Violence 26(10)

100	W. Zou et al.
XX	
101	2007-07-2001

Object	RA (J2000)	Dec (J2000)	Distance (kpc)	Galaxy
1	23 04 12.1	+00 02 27.1	1.0	NGC 2366
2	23 04 12.1	+00 02 27.1	1.0	NGC 2366
3	23 04 12.1	+00 02 27.1	1.0	NGC 2366
4	23 04 12.1	+00 02 27.1	1.0	NGC 2366
5	23 04 12.1	+00 02 27.1	1.0	NGC 2366
6	23 04 12.1	+00 02 27.1	1.0	NGC 2366
7	23 04 12.1	+00 02 27.1	1.0	NGC 2366
8	23 04 12.1	+00 02 27.1	1.0	NGC 2366
9	23 04 12.1	+00 02 27.1	1.0	NGC 2366
10	23 04 12.1	+00 02 27.1	1.0	NGC 2366
11	23 04 12.1	+00 02 27.1	1.0	NGC 2366
12	23 04 12.1	+00 02 27.1	1.0	NGC 2366
13	23 04 12.1	+00 02 27.1	1.0	NGC 2366
14	23 04 12.1	+00 02 27.1	1.0	NGC 2366
15	23 04 12.1	+00 02 27.1	1.0	NGC 2366
16	23 04 12.1	+00 02 27.1	1.0	NGC 2366
17	23 04 12.1	+00 02 27.1	1.0	NGC 2366
18	23 04 12.1	+00 02 27.1	1.0	NGC 2366
19	23 04 12.1	+00 02 27.1	1.0	NGC 2366
20	23 04 12.1	+00 02 27.1	1.0	NGC 2366
21	23 04 12.1	+00 02 27.1	1.0	NGC 2366
22	23 04 12.1	+00 02 27.1	1.0	NGC 2366
23	23 04 12.1	+00 02 27.1	1.0	NGC 2366
24	23 04 12.1	+00 02 27.1	1.0	NGC 2366
25	23 04 12.1	+00 02 27.1	1.0	NGC 2366
26	23 04 12.1	+00 02 27.1	1.0	NGC 2366
27	23 04 12.1	+00 02 27.1	1.0	NGC 2366
28	23 04 12.1	+00 02 27.1	1.0	NGC 2366
29	23 04 12.1	+00 02 27.1	1.0	NGC 2366
30	23 04 12.1	+00 02 27.1	1.0	NGC 2366
31	23 04 12.1	+00 02 27.1	1.0	NGC 2366
32	23 04 12.1	+00 02 27.1	1.0	NGC 2366
33	23 04 12.1	+00 02 27.1	1.0	NGC 2366
34	23 04 12.1	+00 02 27.1	1.0	NGC 2366
35	23 04 12.1	+00 02 27.1	1.0	NGC 2366
36	23 04 12.1	+00 02 27.1	1.0	NGC 2366
37	23 04 12.1	+00 02 27.1	1.0	NGC 2366
38	23 04 12.1	+00 02 27.1	1.0	NGC 2366
39	23 04 12.1	+00 02 27.1	1.0	NGC 2366
40	23 04 12.1	+00 02 27.1	1.0	NGC 2366
41	23 04 12.1	+00 02 27.1	1.0	NGC 2366
42	23 04 12.1	+00 02 27.1	1.0	NGC 2366
43	23 04 12.1	+00 02 27.1	1.0	NGC 2366
44	23 04 12.1	+00 02 27.1	1.0	NGC 2366
45	23 04 12.1	+00 02 27.1	1.0	NGC 2366
46	23 04 12.1	+00 02 27.1	1.0	NGC 2366
47	23 04 12.1	+00 02 27.1	1.0	NGC 2366
48	23 04 12.1	+00 02 27.1	1.0	NGC 2366
49	23 04 12.1	+00 02 27.1	1.0	NGC 2366
50	23 04 12.1	+00 02 27.1	1.0	NGC 2366
51	23 04 12.1	+00 02 27.1	1.0	NGC 2366
52	23 04 12.1	+00 02 27.1	1.0	NGC 2366
53	23 04 12.1	+00 02 27.1	1.0	NGC 2366
54	23 04 12.1	+00 02 27.1	1.0	NGC 2366
55	23 04 12.1	+00 02 27.1	1.0	NGC 2366
56	23 04 12.1	+00 02 27.1	1.0	NGC 2366
57	23 04 12.1	+00 02 27.1	1.0	NGC 2366
58	23 04 12.1	+00 02 27.1	1.0	NGC 2366
59	23 04 12.1	+		

(JERRY) THE MAN NY

[illegible]

Note: Use of the proposed method of detection requires a 1000 or more samples to obtain a probability and for calculating well signal and cell-to-cell effect of cells.

The authors thank Dr. H. N. Maheshwari, Singapore, for the gift of an isolated nucleic acid extract from patient XX.

of the \mathcal{H}_∞ norm of the closed-loop system. The robustness of the closed-loop system to uncertainties in the plant is also considered in the context of the \mathcal{H}_∞ norm. Signal timing and

cell-cell interactions in higher eukaryotes for the development of insecticides, therapeutics and pharmaceutical drugs. The invention discloses genomic RNA sequences (AB101840, AB106111), expressed RNA sequences (AB101840-AB106115) and the encoded proteins (AB067747-AB072072).

The sequence data for this patent did not form part of the published specification, but was obtained in electronic form directly from <http://www.ncbi.nlm.nih.gov/blast/blast.cgi>.

Seq. Sequence 515 AA;

Best Local Similarity 40.48; Prod. No. 1, Apr. 22;
Matches 122; Conservative 10; Mismatches 124; Indels 57; Gaps 14.

[illegible][illegible]

Figure 1: The number of nodes in the network, N , as a function of the number of nodes in the network, N . The number of nodes in the network, N , is plotted on the x-axis, and the number of nodes in the network, N , is plotted on the y-axis. The data points are shown as open circles, and the fitted curve is shown as a solid line. The data points are shown as open circles, and the fitted curve is shown as a solid line. The data points are shown as open circles, and the fitted curve is shown as a solid line.

[illegible]

1b 400 elhyppqitqrkqlllhlldlloppsqwqswvdlvcolltlslldlrelroqpet... 21456

Db	457	1 kps	25.5	11.1	4.7
----	-----	-------	------	------	-----

```

db      479      : | | | | | | |
          slshlscomrpot fpetphdr it --vlpap 508

```

RESULT	7
AB86,2672	
1D AB86,2672 standard; Protein: 515 AA.	

AC	AlHh2672;
XX	
D1	20-MAR-2002 (first entry)

protophila melanogaster polypeptide SEQ ID NO: 14808.
DE
XX
XX
KW Protophila developmental biology; pol; signal; insect; fold;

Prosophtila melanogaster.

XX
XX
XX
XX

27-SEP-2001.

XX 23-MAR 2000; 2000US-191647P,
PR 11-JUL 2000; 2000US-061415A,
PR

.....	(P/EK) PE CORP NY.
PA	
XX	
P1	VENT OF JC) Adams M. 11 FWD) Myers EW

[illegible]

DR WPI: 1999-611301/52.

XX Report kinase-related polypeptides used for the diagnosis and treatment

PT of kinase related diseases and disorders.

XX

AB Disclosures; Page 250 (53); 287pp; English.

XX

00 This sequence represents a novel protein related protein kinase. The

00 invention relates to nucleic acid molecule encoding a kinase polypeptide

00 selected from SIKK2, STK4, STK4, STK5, STK6, STK7, ZC1, ZC2, ZC3,

00 ZC4, KHS2, SHU1, SHU3, GSK3, PAK4 and PAK5. The proteins are used to

00 identify agonists and antagonists, and to raise antibodies. The

00 polynucleotides are useful in gene therapy protocols. The polynucleotides,

00 polypeptides, antibodies, antagonists and agonists may be used to treat

00 diseases such as immune-related disorders and diseases (e.g., rheumatoid

00 arthritis, artherosclerosis, chronic inflammatory bowel disease (e.g.,

00 Crohn's disease), asthma, osteoarthritis, psoriasis, diabetes, sclerosis,

00 fibrosis, autoimmunity, and organ transplantation, chronic inflammatory

00 pelvic disease, multiple sclerosis, organ transplantation, myocardial

00 infarction, cardiovascular disease, stroke, renal failure, oxidative

00 stress-related neurodegenerative disorders (e.g., amyotrophic lateral

00 sclerosis, Parkinson's disease and Leigh syndrome), cancer,

00 cardiomyopathies, ischemic disorders, inflammatory disorders, diabetes

00 mellitus, fibrotic and mesangial disorders. The proteins may also be

00 useful for cell growth regulation (e.g., in wound healing), cell

00 activation, mitosis control, and as immunosuppressants.

XX

SQ Sequence 911 AA;

Query Match	6.08	Score 180.57	108.207	Length 4117
Best Local Similarity	24.88	Prod. No. 1.86 (5%)		
Matches	116	Conservative	55	Mismatches 172
				Indels 137
				Gaps 222

[illegible]

Search completed: June 12, 2002, 09:55:47
Job time: 124 sec

[illegible]

01	NAME	02	ADDRESS	03	CITY	04	STATE	05	ZIP	06	07	08	09	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99
01	NAME	02	ADDRESS	03	CITY	04	STATE	05	ZIP	06	07	08	09	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99
01	NAME	02	ADDRESS	03	CITY	04	STATE	05	ZIP	06	07	08	09	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99
01	NAME	02	ADDRESS	03	CITY	04	STATE	05	ZIP	06	07	08	09	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99
01	NAME	02	ADDRESS	03	CITY	04	STATE	05	ZIP	06	07	08	09	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88											

[illegible]

[illegible]

1. *Chlorophyll a* (Chl *a*)
 2. *Chlorophyll b* (Chl *b*)
 3. *Chlorophyll c* (Chl *c*)
 4. *Chlorophyll d* (Chl *d*)
 5. *Chlorophyll e* (Chl *e*)
 6. *Chlorophyll f* (Chl *f*)
 7. *Chlorophyll g* (Chl *g*)
 8. *Chlorophyll h* (Chl *h*)
 9. *Chlorophyll i* (Chl *i*)
 10. *Chlorophyll j* (Chl *j*)
 11. *Chlorophyll k* (Chl *k*)
 12. *Chlorophyll l* (Chl *l*)
 13. *Chlorophyll m* (Chl *m*)
 14. *Chlorophyll n* (Chl *n*)
 15. *Chlorophyll o* (Chl *o*)
 16. *Chlorophyll p* (Chl *p*)
 17. *Chlorophyll q* (Chl *q*)
 18. *Chlorophyll r* (Chl *r*)
 19. *Chlorophyll s* (Chl *s*)
 20. *Chlorophyll t* (Chl *t*)
 21. *Chlorophyll u* (Chl *u*)
 22. *Chlorophyll v* (Chl *v*)
 23. *Chlorophyll w* (Chl *w*)
 24. *Chlorophyll x* (Chl *x*)
 25. *Chlorophyll y* (Chl *y*)
 26. *Chlorophyll z* (Chl *z*)
 27. *Chlorophyll aa* (Chl *aa*)
 28. *Chlorophyll ab* (Chl *ab*)
 29. *Chlorophyll ac* (Chl *ac*)
 30. *Chlorophyll ad* (Chl *ad*)
 31. *Chlorophyll ae* (Chl *ae*)
 32. *Chlorophyll af* (Chl *af*)
 33. *Chlorophyll ag* (Chl *ag*)
 34. *Chlorophyll ah* (Chl *ah*)
 35. *Chlorophyll ai* (Chl *ai*)
 36. *Chlorophyll aj* (Chl *aj*)
 37. *Chlorophyll ak* (Chl *ak*)
 38. *Chlorophyll al* (Chl *al*)
 39. *Chlorophyll am* (Chl *am*)
 40. *Chlorophyll an* (Chl *an*)
 41. *Chlorophyll ao* (Chl *ao*)
 42. *Chlorophyll ap* (Chl *ap*)
 43. *Chlorophyll aq* (Chl *aq*)
 44. *Chlorophyll ar* (Chl *ar*)
 45. *Chlorophyll as* (Chl *as*)
 46. *Chlorophyll at* (Chl *at*)
 47. *Chlorophyll au* (Chl *au*)
 48. *Chlorophyll av* (Chl *av*)
 49. *Chlorophyll aw* (Chl *aw*)
 50. *Chlorophyll ax* (Chl *ax*)
 51. *Chlorophyll ay* (Chl *ay*)
 52. *Chlorophyll az* (Chl *az*)
 53. *Chlorophyll aza* (Chl *aza*)
 54. *Chlorophyll abz* (Chl *abz*)
 55. *Chlorophyll acz* (Chl *acz*)
 56. *Chlorophyll adz* (Chl *adz*)
 57. *Chlorophyll aez* (Chl *aez*)
 58. *Chlorophyll afz* (Chl *afz*)
 59. *Chlorophyll agz* (Chl *agz*)
 60. *Chlorophyll ahz* (Chl *ahz*)
 61. *Chlorophyll aiz* (Chl *aiz*)
 62. *Chlorophyll ajz* (Chl *ajz*)
 63. *Chlorophyll akz* (Chl *akz*)
 64. *Chlorophyll alz* (Chl *alz*)
 65. *Chlorophyll amz* (Chl *amz*)
 66. *Chlorophyll anz* (Chl *anz*)
 67. *Chlorophyll aoz* (Chl *aoz*)
 68. *Chlorophyll apz* (Chl *apz*)
 69. *Chlorophyll aqz* (Chl *aqz*)
 70. *Chlorophyll arz* (Chl *arz*)
 71. *Chlorophyll asz* (Chl *asz*)
 72. *Chlorophyll atz* (Chl *atz*)
 73. *Chlorophyll auz* (Chl *auz*)
 74. *Chlorophyll avz* (Chl *avz*)
 75. *Chlorophyll awz* (Chl *awz*)
 76. *Chlorophyll axz* (Chl *axz*)
 77. *Chlorophyll ayz* (Chl *ayz*)
 78. *Chlorophyll ayz* (Chl *ayz*)
 79. *Chlorophyll azz* (Chl *azz*)
 80. *Chlorophyll azaa* (Chl *aza*)
 81. *Chlorophyll abz* (Chl *abz*)
 82. *Chlorophyll acz* (Chl *acz*)
 83. *Chlorophyll adz* (Chl *adz*)
 84. *Chlorophyll aez* (Chl *aez*)
 85. *Chlorophyll afz* (Chl *afz*)
 86. *Chlorophyll agz* (Chl *agz*)
 87. *Chlorophyll ahz* (Chl *ahz*)
 88. *Chlorophyll aiz* (Chl *aiz*)
 89. *Chlorophyll ajz* (Chl *ajz*)
 90. *Chlorophyll akz* (Chl *akz*)
 91. *Chlorophyll alz* (Chl *alz*)
 92. *Chlorophyll amz* (Chl *amz*)
 93. *Chlorophyll anz* (Chl *anz*)
 94. *Chlorophyll aoz* (Chl *aoz*)
 95. *Chlorophyll apz* (Chl *apz*)
 96. *Chlorophyll aqz* (Chl *aqz*)
 97. *Chlorophyll arz* (Chl *arz*)
 98. *Chlorophyll asz* (Chl *asz*)
 99. *Chlorophyll atz* (Chl *atz*)
 100. *Chlorophyll auz* (Chl *auz*)
 101. *Chlorophyll avz* (Chl *avz*)
 102. *Chlorophyll awz* (Chl *awz*)
 103. *Chlorophyll axz* (Chl *axz*)
 104. *Chlorophyll ayz* (Chl *ayz*)
 105. *Chlorophyll ayz* (Chl *ayz*)
 106. *Chlorophyll azz* (Chl *azz*)
 107. *Chlorophyll azaa* (Chl *aza*)
 108. *Chlorophyll abz* (Chl *abz*)
 109. *Chlorophyll acz* (Chl *acz*)
 110. *Chlorophyll adz* (Chl *adz*)
 111. *Chlorophyll aez* (Chl *aez*)
 112. *Chlorophyll afz* (Chl *afz*)
 113. *Chlorophyll agz* (Chl *agz*)
 114. *Chlorophyll ahz* (Chl *ahz*)
 115. *Chlorophyll aiz* (Chl *aiz*)
 116. *Chlorophyll ajz* (Chl *ajz*)
 117. *Chlorophyll akz* (Chl *akz*)
 118. *Chlorophyll alz* (Chl *alz*)
 119. *Chlorophyll amz* (Chl *amz*)
 120. *Chlorophyll anz* (Chl *anz*)
 121. *Chlorophyll aoz* (Chl *aoz*)
 122. *Chlorophyll apz* (Chl *apz*)
 123. *Chlorophyll aqz* (Chl *aqz*)
 124. *Chlorophyll arz* (Chl *arz*)
 125. *Chlorophyll asz* (Chl *asz*)
 126. *Chlorophyll atz* (Chl *atz*)
 127. *Chlorophyll auz* (Chl *auz*)
 128. *Chlorophyll avz* (Chl *avz*)
 129. *Chlorophyll awz* (Chl *awz*)
 130. *Chlorophyll axz* (Chl *axz*)
 131. *Chlorophyll ayz* (Chl *ayz*)
 132. *Chlorophyll ayz* (Chl *ayz*)
 133.

THE NEW YORK PUBLIC LIBRARY

Author(s)	Year	Number of students	Number of students with malocclusion	Percentage of malocclusion
Alfaro, J. and J. S. Alfaro	1969	100	27	27%
Alfaro, J. and J. S. Alfaro	1970	100	26	26%
Alfaro, J. and J. S. Alfaro	1971	100	26	26%
Alfaro, J. and J. S. Alfaro	1972	100	26	26%
Alfaro, J. and J. S. Alfaro	1973	100	26	26%
Alfaro, J. and J. S. Alfaro	1974	100	26	26%
Alfaro, J. and J. S. Alfaro	1975	100	26	26%
Alfaro, J. and J. S. Alfaro	1976	100	26	26%
Alfaro, J. and J. S. Alfaro	1977	100	26	26%
Alfaro, J. and J. S. Alfaro	1978	100	26	26%
Alfaro, J. and J. S. Alfaro	1979	100	26	26%
Alfaro, J. and J. S. Alfaro	1980	100	26	26%
Alfaro, J. and J. S. Alfaro	1981	100	26	26%
Alfaro, J. and J. S. Alfaro	1982	100	26	26%
Alfaro, J. and J. S. Alfaro	1983	100	26	26%
Alfaro, J. and J. S. Alfaro	1984	100	26	26%
Alfaro, J. and J. S. Alfaro	1985	100	26	26%
Alfaro, J. and J. S. Alfaro	1986	100	26	26%
Alfaro, J. and J. S. Alfaro	1987	100	26	26%
Alfaro, J. and J. S. Alfaro	1988	100	26	26%
Alfaro, J. and J. S. Alfaro	1989	100	26	26%
Alfaro, J. and J. S. Alfaro	1990	100	26	26%
Alfaro, J. and J. S. Alfaro	1991	100	26	26%
Alfaro, J. and J. S. Alfaro	1992	100	26	26%
Alfaro, J. and J. S. Alfaro	1993	100	26	26%
Alfaro, J. and J. S. Alfaro	1994	100	26	26%
Alfaro, J. and J. S. Alfaro	1995	100	26	26%
Alfaro, J. and J. S. Alfaro	1996	100	26	26%
Alfaro, J. and J. S. Alfaro	1997	100	26	26%
Alfaro, J. and J. S. Alfaro	1998	100	26	26%
Alfaro, J. and J. S. Alfaro	1999	100	26	26%
Alfaro, J. and J. S. Alfaro	2000	100	26	26%
Alfaro, J. and J. S. Alfaro	2001	100	26	26%
Alfaro, J. and J. S. Alfaro	2002	100	26	26%
Alfaro, J. and J. S. Alfaro	2003	100	26	26%
Alfaro, J. and J. S. Alfaro	2004	100	26	26%
Alfaro, J. and J. S. Alfaro	2005	100	26	26%
Alfaro, J. and J. S. Alfaro	2006	100	26	26%
Alfaro, J. and J. S. Alfaro	2007	100	26	26%
Alfaro, J. and J. S. Alfaro	2008	100	26	26%
Alfaro, J. and J. S. Alfaro	2009	100	26	26%
Alfaro, J. and J. S. Alfaro	2010	100	26	26%
Alfaro, J. and J. S. Alfaro	2011	100	26	26%
Alfaro, J. and J. S. Alfaro	2012	100	26	26%
Alfaro, J. and J. S. Alfaro	2013	100	26	26%
Alfaro, J. and J. S. Alfaro	2014	100	26	26%
Alfaro, J. and J. S. Alfaro	2015	100	26	26%
Alfaro, J. and J. S. Alfaro	2016	100	26	26%
Alfaro, J. and J. S. Alfaro	2017	100	26	26%
Alfaro, J. and J. S. Alfaro	2018	100	26	26%
Alfaro, J. and J. S. Alfaro	2019	100	26	26%
Alfaro, J. and J. S. Alfaro	2020	100	26	26%
Alfaro, J. and J. S. Alfaro	2021	100	26	26%
Alfaro, J. and J. S. Alfaro	2022	100	26	26%
Alfaro, J. and J. S. Alfaro	2023	100	26	26%
Alfaro, J. and J. S. Alfaro	2024	100	26	26%
Alfaro, J. and J. S. Alfaro	2025	100	26	26%

1
 2
 3
 4
 5
 6
 7
 8
 9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
 100
 101
 102
 103
 104
 105
 106
 107
 108
 109
 110
 111
 112
 113
 114
 115
 116
 117
 118
 119
 120
 121
 122
 123
 124
 125
 126
 127
 128
 129
 130
 131
 132
 133
 134
 135
 136
 137
 138
 139
 140
 141
 142
 143
 144
 145
 146
 147
 148
 149
 150
 151
 152
 153
 154
 155
 156
 157
 158
 159
 160
 161
 162
 163
 164
 165
 166
 167
 168
 169
 170
 171
 172
 173
 174
 175
 176
 177
 178
 179
 180
 181
 182
 183
 184
 185
 186
 187
 188
 189
 190
 191
 192
 193
 194
 195
 196
 197
 198
 199
 200
 201
 202
 203
 204
 205
 206
 207
 208
 209
 210
 211
 212
 213
 214
 215
 216
 217
 218
 219
 220
 221
 222
 223
 224
 225
 226
 227
 228
 229
 230
 231
 232
 233
 234
 235
 236
 237
 238
 239
 240
 241
 242
 243
 244
 245
 246
 247
 248
 249
 250
 251
 252
 253
 254
 255
 256
 257
 258
 259
 260
 261
 262
 263
 264
 265
 266
 267
 268
 269
 270
 271
 272
 273
 274
 275
 276
 277
 278
 279
 280
 281
 282
 283
 284
 285
 286
 287
 288
 289
 290
 291
 292
 293
 294
 295
 296
 297
 298
 299
 300
 301
 302
 303
 304
 305
 306
 307
 308
 309
 310
 311
 312
 313
 314
 315
 316
 317
 318
 319
 320
 321
 322
 323
 324
 325
 326
 327
 328
 329
 330
 331
 332
 333
 334
 335
 336
 337
 338
 339
 340
 341
 342
 343
 344
 345
 346
 347
 348
 349
 350
 351
 352
 353
 354
 355
 356
 357
 358
 359
 360
 361
 362
 363
 364
 365
 366
 367
 368
 369
 370
 371
 372
 373
 374
 375
 376
 377
 378
 379
 380
 381
 382
 383
 384
 385
 386
 387
 388
 389
 390
 391
 392
 393
 394
 395
 396
 397
 398
 399
 400
 401
 402
 403
 404
 405
 406
 407
 408
 409
 410
 411
 412
 413
 414
 415
 416
 417
 418
 419
 420
 421
 422
 423
 424
 425
 426
 427
 428
 429
 430
 431
 432
 433
 434
 435
 436
 437
 438
 439
 440
 441
 442
 443
 444
 445
 446
 447
 448
 449
 450
 451
 452
 453
 454
 455
 456
 457
 458
 459
 460
 461
 462
 463
 464
 465
 466
 467
 468
 469
 470
 471
 472
 473
 474
 475
 476
 477
 478
 479
 480
 481
 482
 483
 484
 485
 486
 487
 488
 489
 490
 491
 492
 493
 494
 495
 496
 497
 498
 499
 500
 501
 502
 503
 504
 505
 506
 507
 508
 509
 510
 511
 512
 513
 514
 515
 516
 517
 518
 519
 520
 521
 522
 523
 524
 525

THE REAL ABILITY

IBM Corp.
IBM Corp.
IBM Corp.

TRAINING SYSTEM

ALBERT EINSTEIN

SECRET
ZNY
ZCZC
FM
TO
INFO
SUBJ
REF
CITE
DATE
TIME
PAGE
END
BT

THE UNIVERSITY OF CHICAGO

PHILIP R. NICHOLS/PHOTOGRAPHY © 2001 BY A4E.COM
 THE UNIVERSITY OF MICHIGAN LIBRARY

TELEPHONE: (205) 622-4900
FAX: (205) 682-6041

INFORMATION SECTION

THE UNIVERSITY OF CHICAGO

[illegible][illegible]

00	100	101	102	103	104	105	106	107	108	109	110	111	112	113	114	115	116	117	118	119	120	121	122	123	124	125	126	127	128	129	130	131	132	133	134	135	136	137	138	139	140	141	142	143	144	145	146	147	148	149	150	151	152	153	154	155	156	157	158	159	160	161	162	163	164	165	166	167	168	169	170	171	172	173	174	175	176	177	178	179	180	181	182	183	184	185	186	187	188	189	190	191	192	193	194	195	196	197	198	199	200																																																																																																																																																																																																																																																																																																						
00	01	02	03	04	05	06	07	08	09	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	00	01	02	03	04	05	06	07	08	09	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	00	01	02	03	04	05	06	07	08	09	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	00	01	02	03	04	05	06	07	08	09	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	9

RESULT 11
US-08-852-

Sequence 2, Application US/0885274
Patent No. 5830699

GENERAL INFORMATION

APPLICANT: KYRIAKIS, JOH

APPLICANT: Pombo, Gloria M.
APPLICANT: Bonventre, Joseph

NUMBER OF SEQUENCES: 10

CORRESPONDENCE ADDRESS:
ADDRESSER: Fish & Richardson, P.C.

CITY: Boston

STATE: MA
COUNTRY:

COMMITTEE: 02110-28004

COMPUTER READABLE FORM:
MEDIUM TYPE: Diskettes

COMPILER:	IBM Compatible
OPERATING SYSTEM:	Windows

SOFTWARE: FASTSEQ for Windows Version 2.1
CURRENT APPLICATION DATA:

APPLICATION NUMBER: 03/08/852744
FILING DATE: 7-MAY-1997

TABLE 1. 105
PREFRIGERATION DATA

RESULT	4	5
1.1	2000 AA	2000 AA
1.2	2000 AA	2000 AA
1.3	2000 AA	2000 AA
1.4	2000 AA	2000 AA
1.5	2000 AA	2000 AA
1.6	2000 AA	2000 AA
1.7	2000 AA	2000 AA
1.8	2000 AA	2000 AA
1.9	2000 AA	2000 AA
1.10	2000 AA	2000 AA
1.11	2000 AA	2000 AA
1.12	2000 AA	2000 AA
1.13	2000 AA	2000 AA
1.14	2000 AA	2000 AA
1.15	2000 AA	2000 AA
1.16	2000 AA	2000 AA
1.17	2000 AA	2000 AA
1.18	2000 AA	2000 AA
1.19	2000 AA	2000 AA
1.20	2000 AA	2000 AA
1.21	2000 AA	2000 AA
1.22	2000 AA	2000 AA
1.23	2000 AA	2000 AA
1.24	2000 AA	2000 AA
1.25	2000 AA	2000 AA
1.26	2000 AA	2000 AA
1.27	2000 AA	2000 AA
1.28	2000 AA	2000 AA
1.29	2000 AA	2000 AA
1.30	2000 AA	2000 AA
1.31	2000 AA	2000 AA
1.32	2000 AA	2000 AA
1.33	2000 AA	2000 AA
1.34	2000 AA	2000 AA
1.35	2000 AA	2000 AA
1.36	2000 AA	2000 AA
1.37	2000 AA	2000 AA
1.38	2000 AA	2000 AA
1.39	2000 AA	2000 AA
1.40	2000 AA	2000 AA
1.41	2000 AA	2000 AA
1.42	2000 AA	2000 AA
1.43	2000 AA	2000 AA
1.44	2000 AA	2000 AA
1.45	2000 AA	2000 AA
1.46	2000 AA	2000 AA
1.47	2000 AA	2000 AA
1.48	2000 AA	2000 AA
1.49	2000 AA	2000 AA
1.50	2000 AA	2000 AA
1.51	2000 AA	2000 AA
1.52	2000 AA	2000 AA
1.53	2000 AA	2000 AA
1.54	2000 AA	2000 AA
1.55	2000 AA	2000 AA
1.56	2000 AA	2000 AA
1.57	2000 AA	2000 AA
1.58	2000 AA	2000 AA
1.59	2000 AA	2000 AA
1.60	2000 AA	2000 AA
1.61	2000 AA	2000 AA
1.62	2000 AA	2000 AA
1.63	2000 AA	2000 AA
1.64	2000 AA	2000 AA
1.65	2000 AA	2000 AA
1.66	2000 AA	2000 AA
1.67	2000 AA	2000 AA
1.68	2000 AA	2000 AA
1.69	2000 AA	2000 AA
1.70	2000 AA	2000 AA
1.71	2000 AA	2000 AA
1.72	2000 AA	2000 AA
1.73	2000 AA	2000 AA
1.74	2000 AA	2000 AA
1.75	2000 AA	2000 AA
1.76	2000 AA	2000 AA
1.77	2000 AA	2000 AA
1.78	2000 AA	2000 AA
1.79	2000 AA	2000 AA
1.80	2000 AA	2000 AA
1.81	2000 AA	2000 AA
1.82	2000 AA	2000 AA
1.83	2000 AA	2000 AA
1.84	2000 AA	2000 AA
1.85	2000 AA	2000 AA
1.86	2000 AA	2000 AA
1.87	2000 AA	2000 AA
1.88	2000 AA	2000 AA
1.89	2000 AA	2000 AA
1.90	2000 AA	2000 AA
1.91	2000 AA	2000 AA
1.92	2000 AA	2000 AA
1.93	2000 AA	2000 AA
1.94	2000 AA	2000 AA
1.95	2000 AA	2000 AA
1.96	2000 AA	2000 AA
1.97	2000 AA	2000 AA
1.98	2000 AA	2000 AA
1.99	2000 AA	2000 AA
2.00	2000 AA	2000 AA

[illegible]

RESULT	5	
Q95PR3		
ID	Q95PR3	PRELIMINARY: FRT: 45.0 AA.
AC	Q95PR3	
DT	01-DEC-2001 (TREMBL01, 19, created)	
DI	01-DEC-2001 (TREMBL01, 19, last sequence update)	
DI	01-DEC-2001 (TREMBL01, 19, last annotation update)	
GN	1132286p	
OR	CG8726	
OS	<i>Drosophila melanogaster</i> (Fruit fly)	
OC	Insecta; Metazoa; Arthropoda; Tracheata; Hexapoda; Insecta;	
OC	Phylogata; Neoptera; Endopterygota; Diptera; Muscivora;	
OC	Ephydroidea; Drosophilidae; Drosophila	
OX	NCBI_taxid:7227;	

RA SEQUENCING (K.A.)
 RC STRAIN Y, CN BW SP;
 RA Shapiro M., Brookstein L., Ben-David A., Carlson J.,
 RA Champo M., Chavez C., Dorsett V., Farhat E., Fritso E., George K.,
 RA Gonzalez M., Guatin H., Li P., Liao J., Mardar A., Murgall C.,
 RA Nimmo J., Paetzel J., Paradas V., Park S., Pheasantova S., Wan K.,
 RA Yu C., Lewis S.E., Rubin G.M., Colarik S.
 Submitted (oct.2003) to the EMBL/GenBank/CCDB databases.
 RA EMBL: AY061414, AM28962.1;
 NC SQUIDTYPE: 450 AA; 50748 MW; 27346221.71; ORF1;

Country	Match	Score	Year	Length
Best local	Similarity	40.2%	1994	450
Matchups	176	Conservative	1.7%	Indels
				450
				450

[illegible]

[illegible]

Very Much: 11.98; Not at all: 100.00; 8.00;

Query Match	11.9%	56.7%	100%
Best Exact Similarity	41.8%	Protein Not Detected	

[illegible]

[illegible]

CV	521 PF-PAAP11PA 530
	1 1 1 1 1
DB	529 PAAP11MADPDS 540
RESIDUAL	15
Q96J92	
TD	Q96J92 PRELIMINARY; PRY: 1244 AA.
AC	Q96J92;
D1	01-DBP-2001 (TrEMBL; 19, Cleared)
D1	01-DBP-2001 (TrEMBL; 19, Last sequence update)
D1	01-DBP-2001 (TrEMBL; 19, Last annotation update)
DE	HYPERHEMIAL 144.7 KDa PROTEIN.
GN	PERKININ.
OS	Homo sapiens (human);
OC	Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo;
OX	NCBI_TaxID 9606;
RN	11
RP	SEQUENCE FROM N.A.
RC	TISSUE KIDNEY;
RX	MEDLINE 21390047; PubMed 11498581;
RA	Wilson F.H., Tinsol-Nigodome S., Chato K.A., Ishikawa K.,
RA	Nelson-Williams C., Desiter L., Daniel M., Milford D.V., Lipkin S.W.,
RA	Atwood J. M., Feely M.P., Tinsol B., Berland Y., Unwin R.L., Mayan H.,
RA	Simon D.B., Farrel Z., Jouneville X., Lilton R.P.;
RT	"Human Hypertension Caused by Mutations in WNK Kinases.";
RL	Science 293:1107-1112(2001).
DR	EMBL: AF390018; AAK91995.1; -
KW	Hypertetical protein.
SQ	SEQUENCE: 1244 AA; 14473 MW; PAAP11MADPDS191 CDS64-

[illegible]

Wed Jun 12 10:11:02 2002

us-09-684-458-2.rspt

Page 9

Job: 1100000000

